Stacking Exclusivity: How Regulatory Incentives Power Drug Innovation
Impossible d'ajouter des articles
Désolé, nous ne sommes pas en mesure d'ajouter l'article car votre panier est déjà plein.
Veuillez réessayer plus tard
Veuillez réessayer plus tard
Échec de l’élimination de la liste d'envies.
Veuillez réessayer plus tard
Impossible de suivre le podcast
Impossible de ne plus suivre le podcast
Stacking Exclusivity: How Regulatory Incentives Power Drug Innovation
-
Lu par :
-
De :
À propos de ce contenu audio
A pharmacist–turned–regulatory strategist and a 25-year patent attorney walk into a podcast… and blow up the myth that “no composition of matter means no value.”
- Ray and Nicole break down how regulatory exclusivity actually drives drug innovation, often more powerfully than patents.
- Hear how NCE, orphan drug, pediatric, and GAIN Act exclusivity can turn an old or overlooked molecule into a fundable, defensible asset.
- Discover why biologics play by completely different rules, why there’s no Orange Book, and what the mysterious “patent dance” really is.
- Learn how exclusivities can stack (and when they absolutely don’t), including real examples of companies turning five years into ten—or more.
- Get a preview of skinny labeling, the loophole that stops perpetual exclusivity and deserves its own episode.
- Plus: a rapid tour of EU, China, and Japan exclusivity systems and how global rights shape investment strategy.
A fast, clear, myth-busting guide to one of the most misunderstood forces in the life sciences industry.
Vous êtes membre Amazon Prime ?
Bénéficiez automatiquement de 2 livres audio offerts.Bonne écoute !
Aucun commentaire pour le moment